BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12402590)

  • 1. Influence of pH-neutral peritoneal dialysis solution.
    Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
    Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
    Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
    Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis.
    Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
    Adv Perit Dial; 2002; 18():149-53. PubMed ID: 12402608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Necessity of correcting cancer antigen 125 appearance rates by body surface area.
    Kawanishi H; Moriishi M; Harada Y; Sakikubo E; Nagai T; Tsuchiya S
    Adv Perit Dial; 2000; 16():22-5. PubMed ID: 11045255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
    Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
    Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
    Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
    Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis.
    Hasuike Y; Moriguchi R; Hata R; Miyagawa K; Kuragano T; Aizawa M; Yamamoto S; Yanase K; Izumi M; Tanimoto T; Nakanishi T
    Am J Nephrol; 2007; 27(6):622-9. PubMed ID: 17851230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
    Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of systemic and local peritoneal inflammation on peritoneal solute transport rate in new peritoneal dialysis patients: a 1-year prospective study.
    Cho JH; Hur IK; Kim CD; Park SH; Ryu HM; Yook JM; Choi JY; Choi HJ; Choi HJ; Park JW; Do JY; Kim YL
    Nephrol Dial Transplant; 2010 Jun; 25(6):1964-73. PubMed ID: 20100731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
    Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
    Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of dwell time on dialysate cancer antigen 125 appearance rates in patients on continuous ambulatory peritoneal dialysis.
    Akman S; van Westrhenen R; De Waart DR; Hiralall JK; Zweers MM; Krediet RT
    Adv Perit Dial; 2003; 19():24-7. PubMed ID: 14763029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dialysate CA125 in stable CAPD patients: no relation with transport parameters.
    Pannekeet MM; Koomen GC; Struijk DG; Krediet RT
    Clin Nephrol; 1995 Oct; 44(4):248-54. PubMed ID: 8575125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.
    Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
    Adv Perit Dial; 1997; 13():17-22. PubMed ID: 9360644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in peritoneal equilibration test results in patients aged above or below 60 years.
    Grzegorzewska AE; Leander M; Mariak I
    Adv Perit Dial; 2002; 18():33-9. PubMed ID: 12402583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
    Fusshoeller A; Plail M; Grabensee B; Plum J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-peritoneal interleukin-6 system is a potent determinant of the baseline peritoneal solute transport in incident peritoneal dialysis patients.
    Oh KH; Jung JY; Yoon MO; Song A; Lee H; Ro H; Hwang YH; Kim DK; Margetts P; Ahn C
    Nephrol Dial Transplant; 2010 May; 25(5):1639-46. PubMed ID: 20061317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients.
    Lopes Barreto D; Coester AM; Noordzij M; Smit W; Struijk DG; Rogers S; de Waart DR; Krediet RT
    Nephrol Dial Transplant; 2011 Nov; 26(11):3739-44. PubMed ID: 21498425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis.
    Bouts AH; Groothoff JW; van Amstel SP; Zweers MM; Davin JC; Krediet RT
    Adv Perit Dial; 2000; 16():328-31. PubMed ID: 11045322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
    Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
    Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prothrombin fragment 1 + 2 (F1 + 2) in effluent is a useful marker for peritoneal permeability in peritoneal dialysis patients using neutral dialysate.
    Sakurada T; Kojima S; Oishi D; Koitabashi K; Miyamoto M; Shirai S; Shibagaki Y; Yasuda T; Sato T; Kimura K
    Adv Perit Dial; 2011; 27():2-5. PubMed ID: 22073819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.